A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
-
Tucson, Arizona, United States, 85712
-
-
California
-
Los Angeles, California, United States, 90017
-
Sacramento, California, United States, 95821
-
San Diego, California, United States, 92108
-
Westlake Village, California, United States, 91361
-
-
Colorado
-
Denver, Colorado, United States, 80262
-
-
Florida
-
Boynton Beach, Florida, United States, 33472
-
Miami, Florida, United States, 33156
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
-
-
Kentucky
-
Madisonville, Kentucky, United States, 42431
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
-
-
Montana
-
Billings, Montana, United States, 59101
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
-
-
Oregon
-
Portland, Oregon, United States, 97210
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
-
-
Texas
-
Arlington, Texas, United States, 76011
-
Houston, Texas, United States, 77030
-
Houston, Texas, United States, 77058
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
-
-
Virginia
-
Annandale, Virginia, United States, 22003
-
-
Washington
-
Seattle, Washington, United States, 98122
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has a history of genital HSV documented by laboratory testing at screening
- Subject has experienced 4 or more episodes of genital herpes during the past 12 months
Exclusion Criteria:
- Subject is immunocompromised
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
Oral administration of active comparator
|
Oral administration of active comparator.
|
|
Placebo Comparator: 2
Oral administration of placebo
|
Oral administration of placebo.
|
|
Experimental: 3
Dosing regimen 1
|
Oral administration.
|
|
Experimental: 4
Dosing regimen 2
|
Oral administration.
|
|
Experimental: 5
Dosing regimen 3
|
Oral administration.
|
|
Experimental: 6
Dosing regimen 4
|
Oral administration.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection
Time Frame: 17 days
|
17 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics in study patients
Time Frame: 4 days
|
4 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Herpesviridae Infections
- Herpes Simplex
- Herpes Genitalis
- Anti-Infective Agents
- Antiviral Agents
- Valacyclovir
Other Study ID Numbers
Other Study ID Numbers
- 15L-CL-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.